Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemtuzumab ozogamicin + idarubicin + cytarabine + vorinostat
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of gemtuzumab ozogamicin (a CD33-targeting antibody-drug conjugate), idarubicin (an anthracycline), cytarabine (a pyrimidine analog), and vorinostat (a histone deacetylase inhibitor). This regimen has been investigated for the treatment of relapsed or refractory acute myeloid leukemia (AML), particularly in older patients.
02
Targets
CD33 (Myeloid cell surface antigen CD33)DNA polymerase familyTOP2A (DNA topoisomerase II)HDAC (HDAC family)
Beyond the preview
Go deeper on gemtuzumab ozogamicin + idarubicin + cytarabine + vorinostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemtuzumab ozogamicin + idarubicin + cytarabine + vorinostat.